PRCS Praecis Pharmaceuticals (MM)

PRAECIS PHARMACEUTICALS INCORPORATED (NASDAQ:PRCS), today announced that it will report Third Quarter 2005 financial results on Friday, November 4, 2005, before the financial markets open. Company management will host a conference call beginning at 9:00 a.m., EST, with members of the investment community. The Company's conference call may be accessed live by visiting PRAECIS' website at http://www.praecis.com under "Investors" and "Webcast Live." Interested parties also may listen to a replay of the call beginning Friday, November 4, at 12:00 Noon (EST), until midnight Friday, November 11, by calling 888-203-1112 or 719-457-0820, and entering the passcode 175611. PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies that either address unmet medical needs or offer improvements over existing therapies. PRAECIS has a novel MetAP-2 inhibitor in clinical development for non-Hodgkin's lymphoma and solid tumors, as well as an innovative drug discovery technology, Direct Select(TM), which enables the generation and practical use of ultra-large libraries for the discovery of orally active compounds for drug development. PRAECIS has received approval to market Plenaxis(R) in both the United States and Germany.